literature

HIV mutation literature information.

[Genetic analysis of the mutations in HIV-1 infected population in Ecuador].

PMID: 29652972 2018 Revista chilena de infectologia

Abstract: Results The most frequent mutations were M184V/I, K101E/P/H, K103N/S, D30N, M46L/I, I54L/M, V82T/F/A/S/L and L90M in adults and F77L, K103N/S, M46L/I, V82T/F/A/S/L and L90M in children.

Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.

PMID: 29074854 2017 Scientific reports

Abstract: Overall, 7.3% transmitted and 34.3% acquired DRMs were found, including M184V, thymidine analogue mutations (T215F, D67N, K70R, K219Q), NNRTIs (L100I, Y181C, K103N, V108I, Y188L), and PIs (V82L).

Table: V82L

Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).

PMID: 28891788 2017 HIV clinical trials

Method: Primary PI-R substitutions assessed were D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, I54L/M, Q58E, T74P, L76V, V82A/F/L/S/T, I84V, N88S, and L90M in PR.

HIV-1 Transmitted Drug Resistance Mutations in Newly Diagnosed Antiretroviral-Naive Patients in Turkey.

PMID: 26414663 2016 AIDS research and human retroviruses

Abstract: Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M

HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.

PMID: 26558396 2015 PloS one

Table: V82L

Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.

PMID: 24629078 2014 BMC bioinformatics

Result: We modelled the proteins with unusual mutations (L5F, D29V, L63G, L63R, P79L and T91V), natural polymorphisms (L63H andL63S), and drug-resistant mutant PRs with single mutations or patterns of mutations (D30N, V32I, M36I, M46I, I47V, G48V, I50V, I50L, I54M, Q58E, T74P, L76V, V82A

Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey.

PMID: 25397495 2014 Journal of the International AIDS Society

Abstract: RESULTS: The patients had TDRMs to NRTIs (K65R, M184V), NNRTIs (K101E, K103N/S, G190A/E/S, Y181I/C, Y188H/L) and PIs (M46L, I54V, L76V, V82L/T, N83D, I84V, L90M).

Persistence of HIV-1 transmitted drug resistance mutations.

PMID: 23904291 2013 The Journal of infectious diseases

Table: V82L

"Description of the L76V resistance protease mutation in HIV-1 B and ""non-B"" subtypes."

PMID: 23349869 2013 PloS one

5Result: Significant differences in the prevalence of PI RAMs detected with the L76V between subtype B and ""non-B"" samples were found at 4 positions with a higher prevalence of the V32I, M46I/L, V82A/F/L/T/S and L90M mutations in subtype B than in ""non-B"" samples: 10 vs 0%, P = 0.04; 92 vs 82%, P = 0.036; 52 vs 26%, P = 0.0011; and 42 vs 18%, P = 0.002, respectively."

5Result: Then, the most prevalent mutation found with L76V was the V82A/F/L/T/S (52%) in subtype B samples and I84V (36%) in ""non-B"" samples."

Method: In our study, samples with at least one of the major PI RAM of the IAS-USA l

Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

PMID: 22401672 2012 Journal of medicinal chemistry

Introduction: Mutations of V82A/T/F/S/L are very common in PI resistance and show reduced susceptibility to all the clinical PIs except DRV.

Browser Board

Co-occurred Entities

Filtrator